Index Option Calls
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Index Option Calls
No Result
View All Result
Home Latest News

Peter Thiel-backed psychedelic start-up increases stake in Compass Pathways

by
November 29, 2021
in Latest News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Apple CEO Tim Cook praises China’s innovation, long history of cooperation on Beijing visit

The market’s initial reaction to a Fed rate hike is ‘almost always a head fake,’ Jim Cramer says

Atai Life Sciences at the Nasdaq for its IPO, June 18, 2021.

Source: Nasdaq

Atai Life Sciences, the Peter Thiel-backed start-up that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in fellow drug developer Compass Pathways.

Atai bought another 420,000 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%.

The new shares were bought at around $31 each and Atai paid around $12 million in total.

Atai, which is already the largest Compass Pathways shareholder, is planning to increase its stake in Compass Pathways to more like 29% in the coming weeks, according to a source close to the companies who preferred to remain anonymous as the discussions are private.

Christian Angermayer, the founder and chairman of Atai, told CNBC Monday that he believes Compass Pathways is one of the most undervalued and impactful biotech stocks.

Compass Pathways, which Thiel has also invested in, wants to use psilocybin (the compound found in magic mushrooms) to treat depression. It debuted on the Nasdaq stock exchange last September and it has a current market value of $1.4 billion.

Meanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. The stock immediately popped 40% but it has since halved in value and Atai’s current market cap is $1.7 billion.

Billionaire Peter Thiel, PayPal co-founder and chairman of Palantir Technologies, during a news conference in Tokyo, Japan, on Nov. 18, 2019.

Kiyoshi Ota/Bloomberg via Getty Images

Atai, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.

There is growing interest in certain psychedelics after recent clinical studies suggested that some could help patients with a number of mental illnesses, either in combination with traditional solutions or in cases where nothing else has worked.

“The current treatments [for mental health issues] which are out there are definitely not sufficient,” company co-founder Angermayer told CNBC in a previous interview.

“I don’t want to say they don’t work at all because some people are helped by them, but they’re not sufficient.”

Almost a billion people suffer from mental health problems worldwide, according to the World Health Organization.

ShareTweetPin

Related Posts

Apple CEO Tim Cook praises China’s innovation, long history of cooperation on Beijing visit

by
March 25, 2023
0

The world's biggest iPhone factory, located in China and run by Foxconn, faced disruptions in 2022. That is likely to...

The market’s initial reaction to a Fed rate hike is ‘almost always a head fake,’ Jim Cramer says

by
March 25, 2023
0

CNBC's Jim Cramer said on Friday that this week was the latest example of the market gone crazy after a...

Biden says federal deposit insurance could be tapped further if banks fail

by
March 25, 2023
0

The Federal Deposit Insurance Corp. (FDIC) headquarters in Washington, DC, US, on Monday, March 13, 2023. Al Drago | Bloomberg...

Foundation of China’s economic recovery not solid enough, party official says

by
March 25, 2023
0

A general view shows the skyline over the Central Business District in Beijing on February 28, 2023. Jade Gao |...

Jack Dorsey’s Wealth Tumbles $526 Million After Hindenburg Short

by
March 25, 2023
0

S&P 500 3,970.99 +22.27(+0.56%)   Dow 30 32,237.53 +132.28(+0.41%)   Nasdaq 11,823.96 +36.56(+0.31%)   Russell 2000 1,734.92 +14.63(+0.85%)   Crude...

Next Post

Seven High Frequency Indicators for the Economy

Google, Dell Lead Five Diverse Stocks Near Buy Points

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • A Couple Stored IRA Gold at Home. They Owe the IRS More Than $300,000.

    0 shares
    Share 0 Tweet 0
  • A California Couple Spent Eight Years Building Their Dream Retirement Home in Costa Rica

    0 shares
    Share 0 Tweet 0
  • Goldman Sachs says buy these stocks to play Web 3.0 and the metaverse

    0 shares
    Share 0 Tweet 0
  • Goldman Sachs picks new stocks to buy — and says these 5 have over 100% upside

    0 shares
    Share 0 Tweet 0
  • In his final warning, this stock trading wizard — who made big money in bear markets and crashes — called this market a bubble like no other

    0 shares
    Share 0 Tweet 0
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.indexoptioncalls.com
No Result
View All Result
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.indexoptioncalls.com